New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology Perspective DOI Open Access

Liu Liu,

Stephanie L. Graff,

Yihong Wang

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 16 - 16

Published: Dec. 24, 2024

In hormone receptor-positive and HER2-negative breast cancers, a growing number of revolutionary personalized therapies are in clinical use or trials, such as CDK4/6 inhibitors, immune checkpoint PIK3CA inhibitors. Those treatment options largely driven by the presence absence genomic alterations tumor. Therefore, molecular profiling is often performed during disease progression. The most encountered PI3K/AKT/mTOR/PTEN pathway. This review discusses genetic associated with pathway to help clinicians understand drug selection, resistance, interaction from pathologist’s perspective.

Language: Английский

Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis DOI Creative Commons
Bitao Jiang, Lingling Bao,

Songqin He

et al.

Breast Cancer Research, Journal Year: 2024, Volume and Issue: 26(1)

Published: Sept. 20, 2024

Language: Английский

Citations

8
PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials DOI Creative Commons

Minatoullah Habaka,

Gordon R. Daly,

Deborah Shinyanbola

et al.

Current Oncology Reports, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Abstract Purposeof Review Poly (ADP-ribose) polymerases (PARPs) are enzymes essential for detecting and repairing DNA damage through poly-ADP-ribosylation. In cancer, cells with deficiencies in homologous recombination repair mechanisms often become more dependent on PARP-mediated to effectively dsDNA breaks. As such, PARP inhibitors (PARPis) were introduced into clinical practice, serving as a key targeted therapy option synthetic lethality the treatment of cancers deficiency (HRD). Though PARPis currently approved adjuvant setting several cancer types such ovarian, breast, prostate pancreatic their potential role neoadjuvant remains under investigation. This review outlines rationale using PARPi evaluates findings from early ongoing trials. Recent Findings Our analysis indicates that numerous studies have explored HRD-related cancers. The majority trials been performed breast ovarian while phase II/III evidence supporting efficacy limited. Summary Studies investigating Future research should prioritize combination strategies immune checkpoint expand outcome measures include patient satisfaction quality-of-life metrics.

Language: Английский

Citations

0
Impact of sentinel lymph node biopsy on management of older women with clinically node-negative, early-stage, ER+/HER2-, invasive breast cancer: a systematic review and meta-analysis DOI Creative Commons
Gordon R. Daly, Gavin P. Dowling,

Mohammad Said

et al.

Clinical Breast Cancer, Journal Year: 2024, Volume and Issue: 24(8), P. e681 - e688.e1

Published: Aug. 8, 2024

Language: Английский

Citations

1
New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology Perspective DOI Open Access

Liu Liu,

Stephanie L. Graff,

Yihong Wang

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 16 - 16

Published: Dec. 24, 2024

In hormone receptor-positive and HER2-negative breast cancers, a growing number of revolutionary personalized therapies are in clinical use or trials, such as CDK4/6 inhibitors, immune checkpoint PIK3CA inhibitors. Those treatment options largely driven by the presence absence genomic alterations tumor. Therefore, molecular profiling is often performed during disease progression. The most encountered PI3K/AKT/mTOR/PTEN pathway. This review discusses genetic associated with pathway to help clinicians understand drug selection, resistance, interaction from pathologist’s perspective.

Language: Английский

Citations

1